Windtree Therapeutics, Inc.
WINT
Rank in Stocks
#34392
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm... Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016. It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Share Price
$0.0006
Last synced: 2026-11-09
Market Cap
$20.23K
Change (1 day)
0.00%
Change (1 year)
-99.25%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Windtree Therapeutics, Inc. (WINT)
Category
Healthcare
EPS for Windtree Therapeutics, Inc. (WINT)
EPS as of September 2025 TTM: $-8.50
According to Windtree Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-8.50. At the end of 2024 the company had an EPS of $-104.35, an increase over its 2023 EPS of $-4.71K.
EPS history for Windtree Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-8.50 | -91.85% |
| 2024 | $-104.35 | -97.79% |
| 2023 | $-4.71K | -91.59% |
| 2022 | $-56.01K | -54.43% |
| 2021 | $-122.92K | 31.31% |
| 2020 | $-93.62K | -17.26% |
| 2019 | $-113.14K | -89.17% |
| 2018 | $-1.04M | -67.96% |
| 2017 | $-3.26M | -74.54% |
| 2016 | $-12.80M | -40.14% |
| 2015 | $-21.38M | 8.78% |
| 2014 | $-19.66M | -36.59% |
| 2013 | $-31.00M | -13.68% |
| 2012 | $-35.91M | 2.15% |
| 2011 | $-35.15M | -43.64% |
| 2010 | $-62.37M | -57.69% |
| 2009 | $-147.42M | -35.00% |
| 2008 | $-226.80M | -18.37% |
| 2007 | $-277.83M | -33.78% |
| 2006 | $-419.58M | -32.11% |
| 2005 | $-618.03M | 5,350.00% |
| 2004 | $-11.34M | 156,362.13% |
| 2003 | $-7.25K | 8.03% |
| 2002 | $-6.71K | 20.38% |
| 2001 | $-5.57K | -15.34% |
| 2000 | $-6.58K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -284.24% |
US
|
|
| $-7.07 | -16.82% |
US
|
|
| $-5.29 | -37.76% |
AU
|
|
| $12.88 | -251.53% |
BE
|
|
| $21.56 | -353.65% |
NL
|
Questions about Windtree Therapeutics, Inc.'s earnings per share (EPS)
What is Windtree Therapeutics, Inc.'s earnings per share (EPS)?
Windtree Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-8.50, as of Sep 2025.
What was Windtree Therapeutics, Inc.'s earnings per share (EPS) in 2024?
In 2024, Windtree Therapeutics, Inc.'s earnings per share (EPS) was $-104.35, compared with $-4.71K in 2023.
How has Windtree Therapeutics, Inc.'s earnings per share (EPS) changed since 2019?
From 2019 to 2024, Windtree Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($-104.35) and lowest in 2021 ($-122.92K).
How does Windtree Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Windtree Therapeutics, Inc.'s earnings per share (EPS) ($-8.50) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.